Private company

BLOOMIOS, INC.

BLOOMIOS, INC. is a medicinal chemicals and botanical products company.¹ It is headquartered in Santa Barbara, California.¹

Last updated Oct 21, 2026.

Overview

IndustryMedicinal Chemicals & Botanical Products¹
HeadquartersSanta Barbara, California¹
Business address701 Anacapa Street, Suite C, Santa Barbara, Ca 93101²
Filer categoryNon-accelerated filer, Smaller reporting company, Emerging growth company²

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2022

36.7%Gross margin³

-68.1%Operating margin³

-226.7%Net margin⁴

-28.4%Revenue growth, 2022³

Where the money goes

Where each dollar of revenue went, fiscal 2022

Cost of revenueSelling, general and adminInterest

Cost of revenue60¢$3.8M
Selling, general and admin24¢$1.5M
Interest15¢$965.9K

Out of $6.1M in revenue.³⁴ The company lost money this year.

Financial statements

Revenue⁵⁶³$6.1M in 2022

Gross profit⁷⁶³$2.2M in 2022

Operating income⁷⁶³-$4.1M in 2022+788% since 2019

Net income⁸⁶⁴-$13.8M in 2022+137642% since 2018

Fiscal year	2018	2019	2020	2021	2022
Revenue		$0⁵	$1.3M⁶	$8.5M³	$6.1M³
Cost of revenue		$0⁷	$914.8K⁶	$4.7M³	$3.8M³
Gross profit		$0⁷	$401.5K⁶	$3.8M³	$2.2M³
Selling, general and admin		$56.2K⁷	$110.5K⁶	$897.3K³	$1.5M³
Operating expenses				$4.6M³	$6.4M³
Operating income		-$466.4K⁷	-$1.1M⁶	-$800.5K³	-$4.1M³
Interest		$0⁷	$71.0K⁶	$252.5K³	$965.9K³
Income before tax				-$2.0M³	-$13.8M³
Income tax		$0⁷	$0⁶	$0³	$0³
Net income	-$10.0K⁸	-$490.2K⁸	-$1.2M⁶	-$2.0M⁴	-$13.8M⁴
Shares (weighted, basic)				12.6M shares⁶

Total assets⁷⁶³$26.0M in 2022+2488980% since 2019

Total liabilities⁷⁶³$27.3M in 2022+5667% since 2019

Shareholders’ equity⁷⁶³-$1.3M in 2022

Cash⁷⁶³$0 in 2022

Fiscal year	2018	2019	2020	2021	2022
Cash	$0⁷	$1.0K⁶	$72.2K⁶	$270.5K³	$0³
Inventory				$512.2K³	$1.8M³
Current assets		$1.0K⁷	$450.7K⁶	$1.5M³	$2.4M³
Property, plant and equipment				$1.9M³	$1.5M³
Goodwill				$300.0K³	$21.9M³
Total assets		$1.0K⁷	$3.2M⁶	$4.0M³	$26.0M³
Accounts payable				$2.2M³	$2.3M³
Current liabilities		$433.1K⁷	$3.5M⁶	$5.3M³	$27.2M³
Total liabilities		$473.9K⁷	$4.5M⁶	$5.6M³	$27.3M³
Retained earnings				-$6.3M³	-$20.1M³
Shareholders’ equity	$0⁷	-$472.9K⁶	-$1.3M³	-$1.6M³	-$1.3M³
Shares outstanding		12.5M shares⁷	12.5M shares⁶	13.3M shares³	29.9M shares³

Cash from operations⁷⁶³-$6.3M in 2022+10975% since 2019

Fiscal year	2019	2020	2021	2022
Cash from operations	-$57.1K⁷	$821.0K⁶	-$98.5K³	-$6.3M³
Stock-based compensation			$277.3K³	$531.1K³
Cash from investing			-$798.3K³	-$24.2K³
Cash from financing			$1.1M³	$6.1M³

Compare BLOOMIOS, INC. with another company

What it owns

What BLOOMIOS, INC. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

Item	Latest	A year before	Change
Property and equipment, net	$1.5M³ Dec 31, 2022	$1.9M³ Dec 31, 2021	−18.0%
Finance-lease assets	$57.3K³ Dec 31, 2022	$214.2K³ Dec 31, 2021	−73.2%

Investments

Item	Latest	A year before	Change
Cash and cash equivalents	$0³ Dec 31, 2022	$270.5K³ Dec 31, 2021	−100.0%

Intangibles and goodwill

Item	Latest	A year before	Change
Goodwill	$21.9M³ Dec 31, 2022	$300.0K³ Dec 31, 2021	+7188.4%

Inventory

Item	Latest	A year before	Change
Inventory, total	$1.8M³ Dec 31, 2022	$512.2K³ Dec 31, 2021	+246.0%

Leadership

Who has led BLOOMIOS, INC., and when. Pick a name to see everywhere that person has worked.

President

Bryan Glass2019

20202025

PresidentBryan Glass Aug 5, 2019 to Aug 5, 2019¹⁰

Board members and other officers (4)

Chief Business OfficerDouglas S. Rohrer Dec 2, 2022 to Dec 2, 2022¹¹
Pres, Chief Strategy OfficerBarrett Evans Aug 11, 2021 to Aug 11, 2021¹²
Board memberBarrett Evans Aug 11, 2021 to Aug 11, 2021¹²
Board memberBryan Glass Aug 5, 2019 to Aug 5, 2019¹⁰

Former names

XLR MEDICAL CORP.Sep 17, 2004 to Apr 15, 2021²
RELAY MINES LTDMay 1, 2001 to Aug 30, 2004²

Timeline

Mar 29, 20248-K Change in control¹³
Mar 8, 20248-K Debt or obligation accelerated; Other events¹⁴
Nov 20, 20238-K Change in control¹⁵
Jan 5, 20238-K Financial statements and exhibits¹⁶
Nov 25, 20228-K Entered a material agreement; New debt or obligation¹⁷
Oct 31, 20228-K Entered a material agreement; Completed an acquisition or sale; New debt or obligation¹⁸
Aug 2, 20228-K Executive or director change; Shareholder vote¹⁹
Dec 10, 20218-K Entered a material agreement; Unregistered sale of shares²⁰

Filings

44 filings to the SEC since October 2021: 3 annual reports, 7 quarterly reports, 8 major events, 2 insider forms, 24 other. The latest 20:

Mar 29, 202415-12G EDGAR
Mar 29, 20248-K EDGAR
Mar 8, 20248-K EDGAR
Nov 20, 20238-K EDGAR
Nov 20, 202310-Q EDGAR
Nov 15, 2023NT 10-Q EDGAR
Aug 21, 202310-Q EDGAR
Aug 14, 2023NT 10-Q EDGAR
Jun 29, 2023424B3 EDGAR
Jun 28, 2023EFFECT EDGAR
Jun 26, 2023CORRESP EDGAR
Jun 26, 2023S-1/A EDGAR
Jun 26, 2023UPLOAD EDGAR
Jun 20, 2023S-1 EDGAR
May 18, 202310-Q EDGAR
May 15, 2023NT 10-Q EDGAR
Apr 17, 202310-K EDGAR
Mar 31, 2023NT 10-K EDGAR
Jan 5, 20238-K/A EDGAR
Dec 2, 20223 EDGAR

The 44 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

SEC filer profile

How BLOOMIOS, INC. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

Name on EDGARBLOOMIOS, INC.¹
CIK0001138608
Employer ID (EIN)87-4696476¹
Filer statusNon-accelerated filer<br>smaller reporting company<br>emerging growth company¹
Fiscal year endsDecember 31¹
Industry code (SIC)2833 Medicinal Chemicals & Botanical Products¹
SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance¹
Business address701 Anacapa Street, Suite C, Santa Barbara, CA 93101¹
Phone805-222-6330¹
Shares outstanding64,473,246 as of Nov 17, 2023⁴
Public float$4.3M as of Jun 30, 2022³
On EDGAR sinceMay 1, 2001¹
Filings148 in all: 8-K (22), 10QSB (17), 10-Q (15), 3 (14), NT 10-Q (11), NT 10-K (7), UPLOAD (7), 10KSB (6)¹
All 30 form types
4 (6), S-1/A (5), 10-K (4), SC 13D (4), 8-K/A (3), SB-2/A (3), 10-12G/A (2), 10-K/A (2), 15-12G (2), 424B3 (2), 8-A12G (2), CORRESP (2), EFFECT (2), S-1 (2), 10-12G (1), 10QSB/A (1), DEF 14A (1), DEF 14C (1), PRE 14C (1), SB-2 (1), SC 13G (1), SC 14F1 (1)
Latest filingsAnnual report (10-K) Apr 17, 2023
Quarterly report (10-Q) Nov 20, 2023
Proxy statement (DEF 14A) Jul 5, 2022
Latest 8-K (8-K) Mar 29, 2024

Sources

The numbers on this page point here. Each one links to the record it came from.

1
SEC EDGARBLOOMIOS, INC. filings on SEC EDGAR
2
SEC EDGARBLOOMIOS, INC. filings on SEC EDGAR
3
SEC EDGARBLOOMIOS, INC. 10-K for fiscal 2022
4
SEC EDGARBLOOMIOS, INC. 10-K for fiscal 2022
5
SEC EDGARBLOOMIOS, INC. 10-K for fiscal 2019
6
SEC EDGARBLOOMIOS, INC. 10-K for fiscal 2020
7
SEC EDGARBLOOMIOS, INC. 10-K for fiscal 2019
8
SEC EDGARBLOOMIOS, INC. 10-K for fiscal 2018
9
SEC EDGARBLOOMIOS, INC. 10-Q for fiscal 2023
10
SEC EDGARBryan Glass, President
11
SEC EDGARDouglas S. Rohrer, Chief Business Officer
12
SEC EDGARBarrett Evans, Pres, Chief Strategy Officer
13
SEC EDGARChange in control
14
SEC EDGARDebt or obligation accelerated; Other events
15
SEC EDGARChange in control
16
SEC EDGARFinancial statements and exhibits
17
SEC EDGAREntered a material agreement; New debt or obligation
18
SEC EDGAREntered a material agreement; Completed an acquisition or sale; New debt or obligation
19
SEC EDGARExecutive or director change; Shareholder vote
20
SEC EDGAREntered a material agreement; Unregistered sale of shares